DE60214527T2 - Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit - Google Patents
Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit Download PDFInfo
- Publication number
- DE60214527T2 DE60214527T2 DE60214527T DE60214527T DE60214527T2 DE 60214527 T2 DE60214527 T2 DE 60214527T2 DE 60214527 T DE60214527 T DE 60214527T DE 60214527 T DE60214527 T DE 60214527T DE 60214527 T2 DE60214527 T2 DE 60214527T2
- Authority
- DE
- Germany
- Prior art keywords
- flumazenil
- treatment
- administration
- alcohol
- alcohol dependence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 title claims abstract description 81
- 229960004381 flumazenil Drugs 0.000 title claims abstract description 81
- 208000007848 Alcoholism Diseases 0.000 title claims abstract description 33
- 201000007930 alcohol dependence Diseases 0.000 title claims abstract description 31
- 238000011282 treatment Methods 0.000 title claims description 46
- 239000003814 drug Substances 0.000 title abstract description 14
- 238000001990 intravenous administration Methods 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000009467 reduction Effects 0.000 description 11
- 230000008859 change Effects 0.000 description 9
- 208000029650 alcohol withdrawal Diseases 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 229940049706 benzodiazepine Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 150000001557 benzodiazepines Chemical class 0.000 description 5
- 102000004300 GABA-A Receptors Human genes 0.000 description 4
- 108090000839 GABA-A Receptors Proteins 0.000 description 4
- 206010038743 Restlessness Diseases 0.000 description 4
- 206010039897 Sedation Diseases 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000036280 sedation Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 229960004414 clomethiazole Drugs 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 3
- 229960004134 propofol Drugs 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- 206010053164 Alcohol withdrawal syndrome Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000000749 benzodiazepine receptor blocking agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 229940085047 disulfiram 250 mg Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229940083609 fluoxetine 20 mg Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002158 halazepam Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 231100000663 medical toxicology Toxicity 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 229940088697 piracetam 800 mg Drugs 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003598 promazine Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008433 psychological processes and functions Effects 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200100106 | 2001-01-17 | ||
| ES200100106 | 2001-01-17 | ||
| PCT/ES2002/000008 WO2002056964A1 (es) | 2001-01-17 | 2002-01-10 | Empleo de flumazenilo en la elaboración de una medicación para el tratamiento de la dependencia de alcohol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60214527D1 DE60214527D1 (de) | 2006-10-19 |
| DE60214527T2 true DE60214527T2 (de) | 2007-04-05 |
Family
ID=8496426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60214527T Expired - Lifetime DE60214527T2 (de) | 2001-01-17 | 2002-01-10 | Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7348321B2 (https=) |
| EP (1) | EP1374952B1 (https=) |
| JP (2) | JP2004519461A (https=) |
| KR (1) | KR100712570B1 (https=) |
| CN (1) | CN1486205A (https=) |
| AT (1) | ATE338575T1 (https=) |
| AU (1) | AU2002226427B2 (https=) |
| BR (1) | BR0206549A (https=) |
| CA (1) | CA2433833C (https=) |
| CR (1) | CR7049A (https=) |
| CY (1) | CY1107500T1 (https=) |
| DE (1) | DE60214527T2 (https=) |
| DK (1) | DK1374952T3 (https=) |
| ES (1) | ES2269661T3 (https=) |
| IL (1) | IL156798A0 (https=) |
| MX (1) | MXPA03006411A (https=) |
| NZ (2) | NZ539400A (https=) |
| PT (1) | PT1374952E (https=) |
| RU (1) | RU2300378C2 (https=) |
| UA (1) | UA78199C2 (https=) |
| WO (1) | WO2002056964A1 (https=) |
| ZA (1) | ZA200305922B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
| US20060172996A1 (en) * | 2005-02-03 | 2006-08-03 | Halikas James A | Method of preventing relapse in the abstinent substance dependent individual |
| US20060172998A1 (en) * | 2005-02-03 | 2006-08-03 | Halikas James A | Method of preventing relapse in the abstinent substance dependent individual |
| JP2008538748A (ja) | 2005-04-07 | 2008-11-06 | ハイシアム， インコーポレイテッド | 不安、物質乱用及び依存の予防のための改良型方法及び組成物 |
| US20060263304A1 (en) * | 2005-05-23 | 2006-11-23 | Halikas James A | Method of controlling alcohol intake and reversing alcohol effects |
| EP3251670A1 (en) | 2007-08-06 | 2017-12-06 | Biotie Therapies, Inc. | Methods for treating dependence |
| US20110034442A1 (en) * | 2007-08-08 | 2011-02-10 | Jaun Jose Legarda Ibanez | Use and Methods of Use for an Antagonist of the Serotin3 Receptor (5-HT3) and a Selective Modulator of Chloride Channels for the Treatment of Addiction to or Dependence on Medicines/Drugs or Nervous System Disorders |
| US9283212B2 (en) | 2009-02-20 | 2016-03-15 | Palmaya Pty Ltd | Pharmaceutical preparation and delivery system |
| US8387589B2 (en) * | 2009-04-29 | 2013-03-05 | Marine Canada Acqusition Inc. | Position sensor for an output shaft used in a shift and throttle system |
| US20100280684A1 (en) * | 2009-04-29 | 2010-11-04 | Pierre Garon | Synchronization of shift and throttle controls in a marine vessel |
| US8930050B2 (en) * | 2009-04-29 | 2015-01-06 | Marine Canada Acquisition Inc. | Method and system for increasing or decreasing engine throttle in a marine vessel |
| US8347859B2 (en) * | 2009-04-29 | 2013-01-08 | Marine Canada Acquisition Inc. | Automatic throttle calibration in a marine vessel |
| US8406944B2 (en) * | 2010-02-10 | 2013-03-26 | Pierre Garon | Control system and method for starting and stopping marine engines |
| US8845490B2 (en) | 2010-02-10 | 2014-09-30 | Marine Canada Acquisition Inc. | Method and system for delaying shift and throttle commands based on engine speed in a marine vessel |
| US8182396B2 (en) * | 2010-02-10 | 2012-05-22 | Marine Canada Acquisition In.c | Method and system for delaying shift and throttle commands based on engine speed in a marine vessel |
| ES2702848T3 (es) | 2011-02-23 | 2019-03-05 | Coeruleus Ltd | Complejos de flumazenil, composiciones que los comprenden y usos de los mismos |
| RU2468799C1 (ru) * | 2011-08-03 | 2012-12-10 | Общество с ограниченной ответственностью "Урал Крафт" | Способ купирования алкогольного абстинентного синдрома посредством блокады бензодиазепиновых рецепторов |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4316893A (en) * | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US5519017A (en) * | 1990-03-29 | 1996-05-21 | Lts Lohmann Therapie-Systeme Gmbh + Co. Kg | Pharmaceutic formulation for the treatment of alcoholism |
| SE9100860D0 (sv) * | 1991-03-22 | 1991-03-22 | Kabi Pharmacia Ab | New use |
| GB9420010D0 (en) * | 1994-10-01 | 1994-11-16 | Marck Sharp & Dohme Limited | Nucleic acids |
| US20030176456A1 (en) * | 2001-12-21 | 2003-09-18 | June Harry L. | Methods for reducing alcohol cravings in chronic alcoholics |
| US6740677B2 (en) * | 2002-08-19 | 2004-05-25 | Hong Xue | Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids |
-
2002
- 2002-01-10 KR KR1020037009461A patent/KR100712570B1/ko not_active Expired - Fee Related
- 2002-01-10 PT PT02716090T patent/PT1374952E/pt unknown
- 2002-01-10 DE DE60214527T patent/DE60214527T2/de not_active Expired - Lifetime
- 2002-01-10 ZA ZA200305922A patent/ZA200305922B/en unknown
- 2002-01-10 RU RU2003125274/15A patent/RU2300378C2/ru not_active IP Right Cessation
- 2002-01-10 BR BR0206549-5A patent/BR0206549A/pt not_active Application Discontinuation
- 2002-01-10 EP EP02716090A patent/EP1374952B1/en not_active Expired - Lifetime
- 2002-01-10 DK DK02716090T patent/DK1374952T3/da active
- 2002-01-10 JP JP2002557469A patent/JP2004519461A/ja active Pending
- 2002-01-10 CN CNA028038029A patent/CN1486205A/zh active Pending
- 2002-01-10 AT AT02716090T patent/ATE338575T1/de active
- 2002-01-10 NZ NZ539400A patent/NZ539400A/en not_active IP Right Cessation
- 2002-01-10 MX MXPA03006411A patent/MXPA03006411A/es active IP Right Grant
- 2002-01-10 AU AU2002226427A patent/AU2002226427B2/en not_active Ceased
- 2002-01-10 CA CA002433833A patent/CA2433833C/en not_active Expired - Fee Related
- 2002-01-10 WO PCT/ES2002/000008 patent/WO2002056964A1/es not_active Ceased
- 2002-01-10 NZ NZ527583A patent/NZ527583A/xx not_active IP Right Cessation
- 2002-01-10 IL IL15679802A patent/IL156798A0/xx unknown
- 2002-01-10 ES ES02716090T patent/ES2269661T3/es not_active Expired - Lifetime
- 2002-10-01 UA UA2003087768A patent/UA78199C2/uk unknown
-
2003
- 2003-07-15 US US10/621,229 patent/US7348321B2/en not_active Expired - Lifetime
- 2003-08-06 CR CR7049A patent/CR7049A/es unknown
-
2006
- 2006-11-14 CY CY20061101651T patent/CY1107500T1/el unknown
-
2008
- 2008-02-06 US US12/026,643 patent/US20080132492A1/en not_active Abandoned
- 2008-04-28 JP JP2008116697A patent/JP2008201796A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20040092509A1 (en) | 2004-05-13 |
| KR20040020046A (ko) | 2004-03-06 |
| PT1374952E (pt) | 2006-12-29 |
| ES2269661T3 (es) | 2007-04-01 |
| KR100712570B1 (ko) | 2007-05-02 |
| NZ539400A (en) | 2006-04-28 |
| RU2003125274A (ru) | 2005-01-20 |
| EP1374952B1 (en) | 2006-09-06 |
| UA78199C2 (en) | 2007-03-15 |
| AU2002226427B2 (en) | 2006-11-16 |
| ZA200305922B (en) | 2004-08-02 |
| JP2008201796A (ja) | 2008-09-04 |
| MXPA03006411A (es) | 2004-12-02 |
| CR7049A (es) | 2008-02-20 |
| DE60214527D1 (de) | 2006-10-19 |
| CN1486205A (zh) | 2004-03-31 |
| HK1061661A1 (en) | 2004-09-30 |
| US20080132492A1 (en) | 2008-06-05 |
| DK1374952T3 (da) | 2007-01-02 |
| EP1374952A1 (en) | 2004-01-02 |
| RU2300378C2 (ru) | 2007-06-10 |
| JP2004519461A (ja) | 2004-07-02 |
| NZ527583A (en) | 2006-03-31 |
| IL156798A0 (en) | 2004-02-08 |
| CA2433833A1 (en) | 2002-07-25 |
| CY1107500T1 (el) | 2013-03-13 |
| BR0206549A (pt) | 2004-02-25 |
| CA2433833C (en) | 2009-06-02 |
| WO2002056964A1 (es) | 2002-07-25 |
| US7348321B2 (en) | 2008-03-25 |
| ATE338575T1 (de) | 2006-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60214527T2 (de) | Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit | |
| DE2920739C2 (https=) | ||
| DE60021266T2 (de) | Verwendungen von Zusammensetzungen zur Behandlung oder Vorbeugung von Schlafstörungen unter Verwendung von sehr niedrigen Dosen von Cyclobenzaprin | |
| DE69927960T2 (de) | Epiallopregnanolon zur behandlung von krankheiten des cns | |
| DE3688038T2 (de) | Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst. | |
| DE3780618T2 (de) | Verwendung von buspiron zur verbesserung des kurzzeitgedaechtnisses. | |
| DE69232016T2 (de) | Pharmazeutische zusammensetzung, die gamma-hydroxybuttersäure oder das entsprechende lakton enthält, zur behandlung von drogenabhängigkeit und ernährungsstörungen | |
| AT15421U1 (de) | Niedrigfrequente therapie mit glatiramerazetat | |
| DE69425246T2 (de) | Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen | |
| DE3101644A1 (de) | Arzneimittelpraeparate und verfahren zu ihrer herstellung | |
| DE3639378C2 (https=) | ||
| DE60220512T2 (de) | Verwendung von flumazenil zur herstellung eines medikaments für die behandlung von kokainabhängigkeit | |
| DE3343934A1 (de) | M-chlor-(alpha)-tert.-butylaminopropiophenon und seine verwendung zur senkung des cholesterolspiegels | |
| JP2004519461A5 (https=) | ||
| DE3530767C2 (https=) | ||
| DE2758549A1 (de) | Pharmazeutische zubereitung | |
| DE69303305T2 (de) | Mittel zur Behandlung chronischer Ermüdungserscheinungen | |
| DE69308762T2 (de) | Behandlung des Muskulschwunds | |
| DE69821970T2 (de) | Verwendung von CITICOLINE ZUR BEHANDLUNG VON MULTIPLER SKLEROSE | |
| DE602004005000T2 (de) | Methode zur behandlung von niereninsuffizienz | |
| DE60109799T2 (de) | Verwendung von quetiapin für aufmerksamkeitsmangel-hyperaktivitätsstörungen oder verhaltensstörungen | |
| DE3781456T2 (de) | Pharmazeutische zusammensetzung, die eine 8-chlor-benzothiazepin-verbindung enthaelt und ihre verwendung. | |
| DE602005000442T2 (de) | Verwendung von alpha-1-Antitrypsin zur Herstellung eines Medikaments zur Behandlung von Fibromyalgie | |
| DE3136455C2 (de) | Verwendung von Caerulein oder dessen pharmazeutisch verträglichen Salzen bei der Bekämpfung von psychotischen Krankheitszuständen | |
| DE3851669T2 (de) | Verwendung von Gepiron für Medikamente zur Milderung panischer Zustände. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |